GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (LSE:AGL) » Definitions » ROCE %

ANGLE (LSE:AGL) ROCE % : -68.39% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is ANGLE ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ANGLE's annualized ROCE % for the quarter that ended in Dec. 2023 was -68.39%.


ANGLE ROCE % Historical Data

The historical data trend for ANGLE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANGLE ROCE % Chart

ANGLE Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.82 -52.59 -44.30 -55.35 -59.27

ANGLE Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.62 -51.91 -67.20 -51.67 -68.39

ANGLE ROCE % Calculation

ANGLE's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-21.296/( ( (49.868 - 5.25) + (31.183 - 3.943) )/ 2 )
=-21.296/( (44.618+27.24)/ 2 )
=-21.296/35.929
=-59.27 %

ANGLE's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-21.704/( ( (40.164 - 3.934) + (31.183 - 3.943) )/ 2 )
=-21.704/( ( 36.23 + 27.24 )/ 2 )
=-21.704/31.735
=-68.39 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ANGLE  (LSE:AGL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


ANGLE ROCE % Related Terms

Thank you for viewing the detailed overview of ANGLE's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


ANGLE (LSE:AGL) Business Description

Traded in Other Exchanges
Address
10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
ANGLE PLC is active in the healthcare sector in the United Kingdom. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which majority of its revenue is generated from Europe.